Raising the Stakes: Loss of Efflux Pump Regulation Decreases Meropenem Susceptibility in Burkholderia pseudomallei
Author(s) -
Derek S. Sarovich,
Jessica R. Webb,
Matthew C. Pitman,
Linda Viberg,
Mark Mayo,
Rob Baird,
Jennifer Robson,
Bart J. Currie,
Erin P. Price
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy069
Subject(s) - burkholderia pseudomallei , meropenem , medicine , efflux , microbiology and biotechnology , melioidosis , raising (metalworking) , burkholderia , antibiotics , immunology , bacteria , antibiotic resistance , biology , genetics , pathology , geometry , mathematics
Burkholderia pseudomallei, the causative agent of the high-mortality disease melioidosis, is a gram-negative bacterium that is naturally resistant to many antibiotics. There is no vaccine for melioidosis, and effective eradication is reliant on biphasic and prolonged antibiotic administration. The carbapenem drug meropenem is the current gold standard option for treating severe melioidosis. Intrinsic B. pseudomallei resistance toward meropenem has not yet been documented; however, resistance could conceivably develop over the course of infection, leading to prolonged sepsis and treatment failure.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom